Oxaliplatin Injection · 507 days since initial FDA posting
FDA lists Oxaliplatin Injection as To Be Discontinued (Novast Labs).
No availability text on this FDA row.
Oxaliplatin Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Oxaliplatin Injection
- Manufacturer
- Novast Labs
- Dosage Form
- Injection
- Presentation
- Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)
- Package NDC
- 50742-405-10
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Apr 22, 2025
- Last Updated
- Apr 22, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031
Nearby, Other Oxaliplatin Shortage Records
Oxaliplatin Injection
Sandoz Inc.
Injection
Oxaliplatin Injection
Sandoz Inc.
Injection
Oxaliplatin Injection
Novast Labs
Injection
Oxaliplatin Injection
Fresenius Kabi USA, LLC
Injection
Oxaliplatin Injection
Fresenius Kabi USA, LLC
Injection
FDA reason on file: This product is distributed by Ingenus Pharmaceuticals. General shortage guidance lives on the tracker hub.